Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Allergan PLC CEO Brent Saunders warned pharmaceutical manufacturers not to let the election of Donald Trump as president of the US to result in a false sense of security across the industry when it comes to the public controversy over high drug prices.
“I worry today that the pharma industry has a very false sense of relief or security because of a Trump administration and Republican-controlled Congress,” Saunders said, speaking during a panel on drug pricing during the Forbes Healthcare Summit in New York City Dec. 1.
Trump won the election on a populist campaign and the drug pricing issue is a populist issue, he reminded industry. Debate over the cost of pharmaceuticals is not likely to abate because many Americans are “rightfully angry,” Saunders said.
“To think President Trump isn’t a populist, that he won’t jump on the next Epipen scandal and tweet more on a pricing scandal than Hillary Clinton tweeted or anybody else…you are fooling yourself,” he said.
What the drug industry does appear to have won is a short reprieve to address drug pricing without government intervention, Saunders added.
“We have a little bit of time to solve it ourselves, but we don’t have a lot of time,” he said. “The next big scandal will revive the debate.”
Find more content for Scrip here.
Biomedtracker: follow the drug development process
03 Apr 2017
Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.
Scrip: industry news and insights
By Lucie Ellis 22 Feb 2017
Bayer has launched an internal oncology R&D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.
Biomedtracker: follow the drug development process
What’s on the horizon for pharma in 2018? Find out with Biomedtracker’s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.
Topics $name
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
From discovery to patent expiry, and coverage spanning both ethical and generic drugs, Medtrack has you covered. Stay current on key financing, drug and biologics development and drug manufacturing information, all with a single tool.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Looking for more products Product Finder
